GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for ...

RNA-LNP Based, Non-Viral Delivery - RNA-LNP delivery avoids genome integration risks, leaving no genetic footprint. Optimized for PBMCs - The only non-viral kit proven effective for PBMC reprogramming ...

Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 / uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced ...

Human induced pluripotent stem cells (iPSCs) provide a novel platform for developing cell therapies targeting diseases, from rare genetic disorders to cancer, autoimmune diseases and regenerative ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 / uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...